Full-Time

Global Head of Digital Biologics Platform

Large Molecule Research Platform, Lmrp

Confirmed live in the last 24 hours

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

Biotechnology
Healthcare

Expert

Cambridge, MA, USA

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Management
Machine Learning

You match the following Sanofi's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • PhD in Biology, Chemistry, Computational sciences or related field
  • Minimum 15 years of work experience in computational biology, or digital-related discipline
  • Strong leadership and management skills
  • Demonstrated experience managing initiatives and projects in a complex, matrix organization
  • Successful track record in leading projects and teams in Research
  • Recognized thought leadership in the industry in the areas of digital transformation and drug discovery
  • Strong written and oral communication skills
  • Effective interpersonal skills and ability to work transversally
  • Project management experience
Responsibilities
  • Defining and executing on LMRP’s data, digital and AI near-, mid-, long-term strategy in support of Sanofi’s overall business strategy
  • Building of next generation AI-driven biologics discovery and design pipelines together with Digital and global LMRP consisting of the computational engine and requisite laboratory platform and automation technologies
  • Establishing and implementing data governance and acquisition practices across LMR with the support of an imbedded direct report at each LMR site, in collaboration with the R&D Data Office
  • Developing the framework for foundational data exploitation: the base capabilities for exploiting data across LMR, including data and infrastructure for sustaining future advanced applications
  • Defining and implementing AI method validation, acceptance and operationalization processes with the goal of maintaining rigor in the practice of drug discovery
  • Co-managing data and ML operations together with Digital team to ensure state of the art computational platforms
  • Leading the DBx (Digital Biologics) group which consists of a matrix organization of scientists across global LMR that are executing on digital initiatives
  • Overseeing change management within the LMRP organization as it undergoes digital and AI transformation
  • Computational platform innovation: development of new or extension of computational platforms
  • Working in close collaboration with the Head of Innovation to set the strategy and goals to ensure Sanofi attains a leadership position in biologics Innovation
  • Managing the portfolio of strategic external industry and academic collaborations, in partnership with Digital

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline and a global presence. The company's goal is to enhance health outcomes and improve the quality of life for individuals worldwide.

Company Size

10,001+

Company Stage

IPO

Total Funding

$2B

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's Sarclisa approval expands its oncology portfolio in the EU.
  • The partnership with BrightInsight accelerates drug development and improves patient outcomes.
  • The €2 billion share buyback reflects financial confidence and shareholder value commitment.

What critics are saying

  • Increased competition in multiple myeloma treatments may impact Sanofi's market share.
  • Regulatory scrutiny on new drugs like tolebrutinib could delay approvals.
  • The €5 billion share buyback may limit funds for R&D or acquisitions.

What makes Sanofi unique

  • Sanofi's R&D focuses on unmet needs in immunology, oncology, and rare diseases.
  • The company leverages strategic partnerships to enhance digital health solutions and patient outcomes.
  • Sanofi's global reach allows it to navigate diverse regulatory environments effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Webrazzi
Feb 17th, 2025
Sanofi Pharmup Girişimcilik Programı’Nın 6. Dönemi Için Başvurular Başladı! [Sponsorlu İçerik]

Sanofi’nin sağlık sektöründe katma değer yaratacak yenilikçi fikirlerin gelişimine destek olmak için Endeavor ile birlikte hayata geçirdiği Girişimcilik Programı PharmUp’ın 6. dönem başvuruları başladı.Türkiye’nin girişimcilik alanındaki köklü kurumlarından Endeavor iş birliğinde gerçekleşecek 6. dönem takvimine göre, başvurular 25 Şubat 2025 tarihine kadar sanofi.com.tr/tr/pharmup üzerinden yapılabilecek. Yeni dönemin kategorileri Akıllı Sağlık Cihazları ve Diagnostik Çözümler (giyilebilir teknolojiler ve hızlı test araçları), Medikal Eğitim ve İletişim Araçları, Sağlıklı Yaşam Çözümleri, Dijital Sağlık ve Teletıp, Veri Yönetimi ve Analitiği, Kurumsal Dijital Dönüşüm olarak belirlendi.Sağlık sektöründe hastaların hayatını iyileştirme adına dijital çözümler üreten fikirlerin hayat bulduğu program PharmUp’ta seçilecek girişimler, mentorluk desteği ve eğitimler içeren 3 aylık hızlandırma dönemine başlayacak. Bu süreçte ürünlerini olgunlaştıran start-up’lar, sonrasında gerçekleştirilecek Demo Day ile sektörün önde gelen isimlerine projelerini tanıtma şansı bulacak ve Sanofi ile iş birliği fırsatı sunulacak. Bunlara ek olarak, programa katılacak girişimciler arasından belirlenecek kişiler, Paris’te gerçekleşen Viva Technology Fuarı’na Sanofi sponsorluğunda katılma imkânı bulacak.PharmUp’ta 2019’dan beri 27 girişimciye destek verildiİlki 2019 yılında gerçekleşen programa, bugüne kadar toplamda 300’e yakın girişimci başvuru yaptı

PharmiWeb
Feb 7th, 2025
Execution Of A Share Buyback Agreement For Up To €2 Billion

Paris, February 7, 2025. On January 30, 2025, Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, preferably through block trades and in the open market with the purpose of cancellation.A first tranche of this program was announced on February 3, 2025, and executed on February 5, 2025, for an amount of €3 billion, through an off-market block trade with the long-standing shareholder L’Oréal.On February 6, 2025, Sanofi has entered into a mandate with an investment service provider for the second tranche of this program. Under the terms of this mandate, Sanofi will repurchase its own shares for a total consideration of up to €2 billion, between February 7, 2025 and December 31, 2025 at the latest1.About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsSandrine Guendoul | + 33 6 25 09 14 25 | [email protected] Berland | + 1 215 432 0234 | [email protected]éo Le Bourhis | + 33 6 75 06 43 81 | [email protected] Obrist | + 33 6 77 21 27 55 | [email protected] Rouault | + 33 6 70 93 71 40 | [email protected] Gilbert | + 1 516 521 2929 | [email protected] RelationsThomas Kudsk Larsen |+ 44 7545 513 693 | [email protected]é Kaisserian | + 33 6 47 04 12 11 | [email protected] Lauscher | + 1 908 612 7239 | [email protected] Browne | + 1 781 249 1766 | [email protected] Pham | + 33 7 85 93 30 17 | [email protected] Elgoutni | + 1 617 710 3587 | [email protected] Châtelet | + 33 6 80 80 89 90 | [email protected] forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended

PharmiWeb
Jan 22nd, 2025
Sarclisa Approved In The Eu As The First Anti-Cd38 Therapy In Combination With Standard-Of-Care Vrd To Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Approval is based on positive results from the IMROZ phase 3 study, demonstrating Sarclisa in combination with standard-of-care treatment significantly improved PFS, compared to the standard of care alone in TI NDMMRepresents third indication in the EU, including two for the treatment of adult patients with R/R MM, and one in NDMMParis, January 22, 2025. Following the adoption of a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has approved Sarclisa in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplant (ASCT), based on data from the IMROZ phase 3 study. With the expanded marketing authorization, Sarclisa is the first anti-CD38 therapy in combination with VRd in this patient population in the EU.Olivier NatafGlobal Head of Oncology at Sanofi“While there have been many important advancements in multiple myeloma treatment over the past decade, there remains a significant unmet need in the front-line setting, particularly for transplant-ineligible patients. With today’s decision the 27 countries in the EU will have access to a potentially transformative new combination regimen, marking a significant step forward in our mission to make a meaningful difference in multiple myeloma treatment.”In September 2024, the US Food and Drug Administration (FDA) approved Sarclisa in combination with VRd for the treatment of adult patients with NDMM who are not eligible for ASCT, representing the first global approval for Sarclisa in the front-line setting. In addition, the FDA granted orphan drug exclusivity for Sarclisa in the approved indication. Beyond the US and the EU, regulatory submissions for Sarclisa in NDMM not eligible for ASCT are under review in Japan and in China.About SarclisaSarclisa (isatuximab) is a CD38 monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity

Webrazzi
Dec 24th, 2024
Sanofi’Nin Girişimcilik Programı Care4Rare'In Demo Day'Inde Sunum Yapan Girişimler

Sürdürülebilir sağlık için ortak hareket etme vizyonuyla çalışmalar yürüten TÜSAP Platformu, sağlık sektörünün mevcut durumundan yola çıkarak vizyon tartışmaları yapmak ve sektörün geleceğini etkileyecek nitelikli bilgiler üretmek amacıyla 40. Vizyon Toplantısı’nı, Sanofi’nin katkılarıyla düzenledi.Zirvede Sanofi’nin PharmUp Girişimci Destek Programı kapsamında hayata geçirilen, metabolik ve nadir bir hastalık grubu olan Lizozomal Depo Hastalıkları odağında çözüm geliştiren girişimcilere yönelik başlattığı Care4Rare projesinin Demoday etkinliği gerçekleştirildi.Care4Rare programı, Sanofi’nin Sağlık Bakanlığı Nadir Hastalıklar Sağlık Strateji Belgesi ve Eylem Planı’na uygun birçok dijital çözüm, yaklaşım, fikir ve paydaşlarla iş birliği fırsatları yaratmayı hedeflediği projesi. Lizozomal Depo Hastalıkları başta olmak üzere nadir hastalıklara sahip hastaların tanı, tedavi ve günlük yaşam süreçlerindeki öncelikli sorunlarına girişimci gözü ile bulunan çözümlerin hayata geçirilmesi için kapsamlı destekler sunuluyor.Care4Rare'in Demo Day'inde sunum yapan girişimler şu şekilde:Umaxlife: Biyomarkerlara entegre olarak veri toplayabilen, derin öğrenme ile akıl sağlığının insan bedenine etkisini ölçümleyen dijital terapötik platform.Inorare: Nadir hastalıklarla mücadele edenlerin en çok kullandığı medikal cihazlardan biri olan TAK kateterlerin ev ortamında kullanıcı tarafından en az 10 kez sterilize edilip tekrar kullanımını sağlayacak bir kişisel sterilizasyon sunuyor.Pons: Hastane dışında yapay zeka destekli mobil ultrason teknolojisi ile erken aşama yüksek riskli kanser vakalarının tespitini mümkün kılan teknolojiye sahip girişim.RareGlow: Hastalığın seyrine göre fizyoterapistin ailelere verdiği egzersiz programını 3 boyutlu bir modelle uygulamaya entegre ediyor.RareSum: Doktorların yüklediği anonim hasta profillerini inceleyen, bugüne kadar yayınlanmış vaka çalışmalarıyla eşleşme sağlayan, doktorun teşhis ve tedavisini bilimsel kanıtlarla desteklemesini sağlayan, yapay zeka tabanlı karar destek mekanizması

Hit Consultant
Dec 17th, 2024
Brightinsight, Sanofi To Build Drug Companion Apps For Its Major Specialty Therapies

What You Should Know:– BrightInsight, Inc., a provider of regulated digital health solutions, has announced an expanded multi-year partnership with Sanofi, a global biopharmaceutical company. This expanded partnership builds on a successful collaboration that began in 2022 when Sanofi selected the BrightInsight Platform to accelerate the development of a SaMD for one of its specialty care medicines.– The goal of the collaboration aims to accelerate Sanofi’s drug development timeline and improve patient outcomes through innovative digital health solutions.Accelerating Time-to-Market for New TherapiesSanofi aims to cut its drug development timeline in half, and this partnership with BrightInsight will play a key role in achieving that goal. By leveraging BrightInsight’s platform and technology, Sanofi can streamline the development and deployment of digital health solutions that support clinical trials, enhance patient engagement, and improve medication adherence.Enhancing Patient Experience with “MyWay”Under the expanded partnership, Sanofi will utilize BrightInsight’s “MyWay” mobile application, a Software as a Medical Device (SaMD) solution designed to empower patients in managing their health conditions. MyWay offers several key features:Symptom Tracking: Allows patients to track their symptoms, such as flares or disease progression.Allows patients to track their symptoms, such as flares or disease progression. Medication Management: Helps patients manage their medications, including tracking injections and adherence.Helps patients manage their medications, including tracking injections and adherence. Financial Tracking: Enables patients to track medical expenses in select countries.Enables patients to track medical expenses in select countries